featured
Apremilast Is Safe and Effective for Moderate to Severe Palmoplantar Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Apremilast, an Oral Phosphodiesterase-4 Inhibitor, in the Treatment of Palmoplantar Psoriasis: Results of a Pooled Analysis From Phase II PSOR-005 and Phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) Clinical Trials in Patients With Moderate to Severe Psoriasis
J Am Acad Dermatol 2016 Mar 24;[EPub Ahead of Print], R Bissonnette, DM Pariser, NR Wasel, J Goncalves, RM Day, R Chen, M SebastianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.